| Venetoclax and navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma VA Pullarkat, NJ Lacayo, E Jabbour, JE Rubnitz, A Bajel, TW Laetsch, ... Cancer discovery 11 (6), 1440-1453, 2021 | 190 | 2021 |
| Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma LJ Costa, EA Stadtmauer, G Morgan, G Monohan, T Kovacsovics, ... Blood 132, 303, 2018 | 91 | 2018 |
| Targeting BCL‐2 with venetoclax and dexamethasone in patients with relapsed/refractory t (11; 14) multiple myeloma JL Kaufman, C Gasparetto, FH Schjesvold, P Moreau, C Touzeau, ... American journal of hematology 96 (4), 418-427, 2021 | 86 | 2021 |
| Hypoxia promotes tau hyperphosphorylation with associated neuropathology in vascular dysfunction L Raz, K Bhaskar, J Weaver, S Marini, Q Zhang, JF Thompson, ... Neurobiology of disease 126, 124-136, 2019 | 76 | 2019 |
| Long-term follow-up of patients with relapsed or refractory non–Hodgkin lymphoma treated with Venetoclax in a phase I, first-in-human study MS Davids, AW Roberts, VP Kenkre, WG Wierda, A Kumar, TJ Kipps, ... Clinical Cancer Research 27 (17), 4690-4695, 2021 | 53 | 2021 |
| Safety and efficacy of navitoclax, a BCL-2 and BCL-XL inhibitor, in patients with relapsed or refractory lymphoid malignancies: results from a phase 2a study S de Vos, JP Leonard, JW Friedberg, J Zain, K Dunleavy, ... Leukemia & lymphoma 62 (4), 810-818, 2021 | 51 | 2021 |
| Improving depth of thinking in online discussion boards SS Williams, A Jaramillo, JC Pesko Quarterly Review of Distance Education 16 (3), 45, 2015 | 46 | 2015 |
| Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited-duration therapy S Ma, JF Seymour, DM Brander, TJ Kipps, MY Choi, MA Anderson, ... Blood, The Journal of the American Society of Hematology 138 (10), 836-846, 2021 | 35 | 2021 |
| Biomarkers identify the Binswanger type of vascular cognitive impairment E Barry Erhardt, JC Pesko, J Prestopnik, J Thompson, A Caprihan, ... Journal of Cerebral Blood Flow & Metabolism 39 (8), 1602-1612, 2019 | 27 | 2019 |
| Phase I/II study evaluating the safety and efficacy of venetoclax in combination with dexamethasone as targeted therapy for patients with t (11; 14) relapsed/refractory … JL Kaufman, C Gasparetto, FH Schjesvold, P Moreau, C Touzeau, ... Blood 134, 926, 2019 | 22 | 2019 |
| First analysis from a phase 1/2 study of venetoclax in combination with daratumumab and dexamethasone,+/-Bortezomib, in patients with relapsed/refractory multiple myeloma N Bahlis, R Baz, S Harrison, H Quach, SJ Ho, AJ Vangsted, P Moreau, ... Blood 134, 925, 2019 | 14 | 2019 |
| Parametric boostrap and objective Bayesian testing for heteroscedastic one-way ANOVA G Zhang, R Christensen, J Pesko Statistics & Probability Letters 174, 109095, 2021 | 12 | 2021 |
| MMP-9 inhibitors impair learning in spontaneously hypertensive rats L Raz, Y Yang, J Thompson, S Hobson, J Pesko, S Mobashery, M Chang, ... PLoS One 13 (12), e0208357, 2018 | 12 | 2018 |
| Impact of venetoclax monotherapy on the quality of life of patients with relapsed or refractory chronic lymphocytic leukemia: results from the phase 3b VENICE II trial T Cochrane, A Enrico, D Gomez-Almaguer, E Hadjiev, E Lech-Maranda, ... Leukemia & Lymphoma 63 (2), 304-314, 2022 | 11 | 2022 |
| Identification of recurrent genomic alterations in the apoptotic machinery in chronic lymphocytic leukemia patients treated with venetoclax monotherapy R Popovic, F Dunbar, C Lu, K Robinson, D Quarless, SE Warder, ... American Journal of Hematology 97 (2), E47, 2022 | 8 | 2022 |
| ReVenG: a phase 2 study of venetoclax plus obinutuzumab retreatment in patients with relapsed chronic lymphocytic leukemia MS Davids, K Fischer, S Robrecht, C Zhang, IE Ahn, MP Lurà, W Sinai, ... Blood 138, 2634, 2021 | 7 | 2021 |
| Venetoclax and navitoclax in pediatric patients with acute lymphoblastic leukemia and lymphoblastic lymphoma JE Rubnitz, TB Alexander, TW Laetsch, SL Khaw, VA Pullarkat, ... Blood 136, 12-13, 2020 | 3 | 2020 |
| Debulking before initiation of venetoclax therapy in untreated patients with chronic lymphocytic leukemia: results from a phase 3b study IW Flinn, D Andorsky, J Melear, S Manda, B Anz III, K Kolibaba, H Yimer, ... Blood 138, 3725, 2021 | 1 | 2021 |
| Posterior brain sensorimotor recruitment for inhibition of delayed responses in children KTR Ciesielski, C Bouchard, I Solis, BA Coffman, D Tofighi, JC Pesko Experimental Brain Research 239 (11), 3221-3242, 2021 | 1 | 2021 |
| CLL-076: Phase 3b study to evaluate debulking regimens prior to initiating venetoclax therapy in untreated patients with chronic lymphocytic leukemia J Sharman, D Andorsky, J Melear, S Manda, B Anz III, KKH Yimer, J Burke, ... Clinical Lymphoma Myeloma and Leukemia 20, S219-S220, 2020 | 1 | 2020 |
